Mercado mundial de espirómetros: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de espirómetros

El mercado de los espirómetros sigue avanzando gracias a las innovaciones en dispositivos portátiles que integran conectividad inalámbrica para la monitorización remota. Los métodos más recientes incluyen análisis basados ​​en inteligencia artificial para una evaluación precisa de la función pulmonar. Las tecnologías como los sensores de flujo ultrasónico mejoran la precisión y la experiencia del usuario. El crecimiento está impulsado por la creciente prevalencia de enfermedades respiratorias y la demanda de soluciones de atención médica domiciliaria, lo que configura una sólida perspectiva de mercado.                                

El tamaño del mercado global de espirómetros se valoró en USD 789,04 millones en 2023 y se proyecta que alcance los USD 1.805,31 millones para 2031, con una CAGR del 10,9% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Market Definition

A spirometer is a medical device used to measure lung function and capacity. It works by recording the volume of air inhaled and exhaled by the lungs during breathing exercises. Spirometry tests are crucial in diagnosing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and monitoring lung health in various clinical settings. This device aids in assessing lung function for accurate diagnosis and treatment planning.           

Spirometer Market Dynamics

Drivers

• Increasing Respiratory Diseases

The rising prevalence of respiratory diseases such as COPD and asthma globally has significantly increased the demand for spirometry devices. These conditions require accurate diagnosis and ongoing monitoring of lung function, which spirometers provide. For instance, in 2023, the global spirometer market saw a notable surge in sales, driven by healthcare facilities' urgent need to manage and treat respiratory illnesses effectively through early detection and precise diagnostic tools such as spirometry.

• Integration with Electronic Health Records (EHRs)

Integration of spirometry devices with Electronic Health Records (EHRs) automates data capture, analysis, and storage, reducing manual entry errors and enhancing healthcare provider efficiency. For instance, seamless integration allows clinicians to access patients' historical spirometry data instantly during consultations, facilitating quicker and more informed treatment decisions. This integration not only improves patient care but also drives market expansion by demonstrating tangible benefits in terms of operational efficiency and patient outcomes.

Opportunities

• Rising Demand for Telemedicine and Remote Monitoring

The rising demand for telemedicine and remote monitoring, accelerated by the COVID-19 pandemic, has created significant opportunities in the spirometer market. Home-based spirometry devices enable patients to monitor lung function remotely, enhancing access to healthcare and reducing the need for frequent clinic visits. This trend has spurred innovation among device manufacturers, leading to the development of user-friendly, portable spirometers that cater to the growing preference for telehealth solutions.

• Rising Patient-Centric Care Initiatives

Rising patient-centric care initiatives emphasize personalized treatment plans tailored to individual health needs. Spirometry, pivotal in monitoring chronic respiratory conditions such as COPD, aligns with this trend by enabling precise diagnosis and ongoing management at the patient's convenience. This shift expands market opportunities as healthcare providers increasingly integrate spirometry into comprehensive, patient-centered care strategies, ensuring better health outcomes through proactive monitoring and tailored interventions.

Restraints/Challenges

• Risk of Infection Transmission

The risk of infection transmission through spirometry, involving direct contact with patients' breath, poses significant operational challenges in healthcare settings. Stringent infection control measures are essential but add to the complexity and cost of using spirometers. This risk can deter adoption and increase reluctance among healthcare providers to use spirometry devices, potentially hindering market growth and adoption rates. 

• High Cost of Devices

The high cost of spirometers, particularly advanced models for clinical use, poses a significant barrier to adoption in smaller healthcare facilities and regions with constrained budgets. This financial restraint hinders market penetration and limits accessibility to essential respiratory diagnostic tools. As a result, healthcare providers in these settings may face challenges in acquiring necessary equipment to effectively diagnose and manage respiratory conditions. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2022, RxCap, Inc. partnered with ZEPHYRx to integrate ZEPHYRx's online spirometry platform with RxCap's remote surveillance system. This collaboration enables RxCap's corporate clients, including healthcare providers and insurers, to monitor the lung health of patients with severe respiratory diseases remotely
• In August 2022, AstraZeneca collaborated with Alveofit to deploy IoT-enabled portable spirometers in U.S. clinics. These handheld devices connect to the internet, enabling online patient tracking and tele-spirometry. Integrated with comprehensive care management systems, they enhance respiratory care accessibility and efficiency
• In April 2021, Vitalograph launched the next-generation Pneumotrac spirometer in the U.S. This device, paired with Spirotrac PC software, is designed for precise respiratory diagnosis in both adult and pediatric patients, enhancing diagnostic capabilities and clinical management in respiratory healthcare

Spirometer Market Scope

The market is segmented on the basis of type, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Software
• Devices
  • Table-Top Spirometer
  •  Hand-Held Spirometer
  •  PC Based Spirometer
• Consumables and Accessories

Technology

• Volume Measurement Spirometer
• Flow Measurement Spirometer
• Peak Flow Meter

 Mechanism

• Flow-Sensing Spirometer
• Peak Flow Meters

Disease

• Bronchitis
• Emphysema
• Chronic Obstructive Lung Disease
• Lung Cancer
• Others

 Disposable Components

• Filters
• Sensors
• Tubes

 Application

• Asthma
• COPD
• Cystic Fibrosis
• Pulmonary Fibrosis
• Others

 End-User

• Hospitals
• Clinics
• Homecare

 Distribution Channel

• Over the Counter
• Direct Tender

Spirometer Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is projected to dominate the spirometer market due to the high prevalence of chronic obstructive pulmonary disease (COPD). This region's advanced healthcare infrastructure, coupled with robust research and development activities, contributes to the significant adoption of spirometry devices for the diagnosis and management of respiratory conditions.

Asia-Pacific is expected to witness significant growth in the spirometer market during the forecast period. This growth is driven by improving primary care initiatives aimed at early diagnosis and management of chronic lung diseases such as asthma and COPD, fostering increased adoption of spirometry technologies across the region.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Crecimiento de la infraestructura de salud Base instalada y penetración de nuevas tecnologías

El mercado también le ofrece un análisis detallado del mercado para cada país: crecimiento del gasto sanitario en equipos de capital, base instalada de diferentes tipos de productos para el mercado, impacto de la tecnología mediante curvas de línea de vida y cambios en los escenarios regulatorios de la atención sanitaria y su impacto en el mercado. Los datos están disponibles para el período histórico 2016-2021.

Análisis del panorama competitivo y de la cuota de mercado de los espirómetros

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Algunos de los principales actores que operan en el mercado son:

• F. Hoffmann-La Roche, Ltd. (Suiza)
• Mylan NV (Estados Unidos)
• Sanofi (Francia)
• Pfizer Inc. (Estados Unidos)
• GSK plc. (Reino Unido)
• Novartis AG (Suiza)
• Bayer AG (Alemania)
• Merck & Co., Inc. (Estados Unidos)
• AstraZeneca (Reino Unido)
• Cipla (Estados Unidos)
• Merck KGaA (Alemania)
• LEO Pharma A/S (Dinamarca)
•  Industrias farmacéuticas Sun Ltd. (India)
• Aurobindo Pharma (India)
• Lupino (India)
• Fresenius Kabi AG (Alemania)
•  Amneal Pharmaceuticals LLC. (Estados Unidos)

SKU-1373